28 March 2023 | Tuesday | News
SOF-VACTM blocks inflammation receptors, thereby blocking inflammation and reducing vaccine side effects.
A lead candidate has now been selected for further development. Under the ongoing collaboration with the Hudson Institute of Medical Research, the team has synthesised a novel ‘vaccine enhancer’ called SOF-VACTM.
This preclinical technology aims to make a broad range of mRNA vaccines safer by reducing inflammation associated with mRNA vaccines. In addition, the technology has the potential to support more cost-effective mRNA vaccine manufacturing.
The team’s recent development work on SOF-VACTM has shown strong in vitro and in vivo activity against inflammation. SOF-VACTM represents a first-in-class achievement as the smallest known molecule of its type to have demonstrated this activity. The major advantage of such a small molecule is it reduces the risk of off-target effects compared to larger molecules of this type.
Most Read
Bio Jobs
News
Editor Picks